Aegerion Pharma (AEGR) Misses Q2 EPS by 34c

Aegerion Pharma (NASDAQ: AEGR) reported Q2 EPS of ($0.72), $0.34 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $44.5 million versus the consensus estimate of $35.5 million.

For earnings history and earnings-related data on Aegerion Pharma (AEGR) click here.

You May Also Be Interested In

• Piper Sandler sees Google TPU sales hitting $104BN by 2028
• Piper Sandler's Focus Idea: 'Allstate (ALL): Underappreciated Underwriting & Return Capacity at Low Price'
• ZoomInfo Technologies (GTM) PT Lowered to $4.25 at DA Davidson to Reflect Sector Headwinds